DK2009000T3 - Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme - Google Patents

Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme

Info

Publication number
DK2009000T3
DK2009000T3 DK08015449.5T DK08015449T DK2009000T3 DK 2009000 T3 DK2009000 T3 DK 2009000T3 DK 08015449 T DK08015449 T DK 08015449T DK 2009000 T3 DK2009000 T3 DK 2009000T3
Authority
DK
Denmark
Prior art keywords
receptor inverse
compound
neurodegenerative diseases
therapeutics
efficacy
Prior art date
Application number
DK08015449.5T
Other languages
English (en)
Inventor
Robert E Davis
Mark R Brann
Norman Nash
Carl-Magnus A Andersson
Allan K Uldam
M David Weiner
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2009000(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of DK2009000T3 publication Critical patent/DK2009000T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
DK08015449.5T 2003-01-16 2004-01-15 Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme DK2009000T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44140603P 2003-01-16 2003-01-16
US47934603P 2003-06-17 2003-06-17
EP04702584A EP1587789B1 (en) 2003-01-16 2004-01-15 Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DK2009000T3 true DK2009000T3 (da) 2011-09-05

Family

ID=32776052

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04702584T DK1587789T3 (da) 2003-01-16 2004-01-15 Selektiv serotomin - 2A/2C - receptor - inverse - agonister som terapeutiske midler til neurodegenerative sygdomme
DK08015449.5T DK2009000T3 (da) 2003-01-16 2004-01-15 Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04702584T DK1587789T3 (da) 2003-01-16 2004-01-15 Selektiv serotomin - 2A/2C - receptor - inverse - agonister som terapeutiske midler til neurodegenerative sygdomme

Country Status (22)

Country Link
US (17) US7601740B2 (da)
EP (2) EP2009000B1 (da)
JP (2) JP5184777B2 (da)
KR (1) KR101095939B1 (da)
CN (3) CN101780080B (da)
AT (2) ATE512136T1 (da)
AU (1) AU2004206886B2 (da)
BR (1) BRPI0406591B8 (da)
CA (1) CA2512639C (da)
CY (1) CY1108642T1 (da)
DE (1) DE602004016288D1 (da)
DK (2) DK1587789T3 (da)
ES (2) ES2367135T3 (da)
HK (2) HK1126776A1 (da)
MX (1) MXPA05007568A (da)
NZ (1) NZ541146A (da)
PT (1) PT1587789E (da)
RU (2) RU2332401C2 (da)
SG (1) SG170617A1 (da)
SI (2) SI1587789T1 (da)
WO (1) WO2004064738A2 (da)
ZA (1) ZA200505680B (da)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
CN100372848C (zh) 2001-12-28 2008-03-05 阿卡蒂亚药品公司 作为单胺受体调节剂的螺氮杂环化合物
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
BR0312217A (pt) 2002-06-24 2005-05-10 Acadia Pharm Inc Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
RU2332401C2 (ru) 2003-01-16 2008-08-27 Акадиа Фармасьютикалз Инк. Селективные обратные агонисты серотонин 2а/2с рецептора, применяемые в качестве лекарственных средств при нейродегенеративных заболеваниях
AU2004206931A1 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7868176B2 (en) * 2004-09-27 2011-01-11 Acadia Pharmaceuticals, Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
TW200806321A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment or prevention of psychotic disorders
US20080051429A1 (en) * 2006-04-19 2008-02-28 Van Kammen Daniel Use of 4-amino-piperidines for treating sleep disorders
EP2037918A2 (en) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
US20080039535A1 (en) * 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treating neurological disorders
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
KR101141185B1 (ko) * 2007-01-26 2012-07-12 오쓰까 세이야꾸 가부시키가이샤 치료의 제안된 효능 검출용 마커
PL2134330T3 (pl) * 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
AU2008302079A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. Co-administration of pimavanserin with other agents
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CN102264354B (zh) 2008-10-28 2015-03-25 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA2870303A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2014085362A1 (en) 2012-11-27 2014-06-05 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR20230023817A (ko) 2013-12-03 2023-02-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
TWI703130B (zh) * 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
CN104961671B (zh) * 2014-09-05 2018-01-02 苏州晶云药物科技有限公司 N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
KR20160103548A (ko) * 2015-01-28 2016-09-01 주식회사 제네리스코리아 신경정신계 장애의 치료를 위한 조성물 및 방법
WO2016141003A1 (en) 2015-03-02 2016-09-09 Teva Pharmaceutical Industries Ltd. Processes and intermediates for the preparation of pimavanserin
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
DK3325444T3 (da) 2015-07-20 2021-10-04 Acadia Pharm Inc Fremgangsmåder til fremstilling af n-(4-fluorbenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamid og dets tartratsalt og polymorf form c
CZ2015601A3 (cs) 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CZ2015688A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů
CN105523993A (zh) * 2015-12-28 2016-04-27 重庆两江药物研发中心有限公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
RS64027B1 (sr) 2016-03-22 2023-03-31 Helsinn Healthcare Sa Benzenesulfonil-asimetrične uree i njihove medicinske upotrebe
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3436010B1 (en) 2016-03-29 2021-03-10 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
CN107343887A (zh) * 2016-05-06 2017-11-14 常州爱诺新睿医药技术有限公司 一种无定型半酒石酸匹莫范色林与药用辅料的固体分散体及其制备方法
CN106179449B (zh) * 2016-07-18 2018-11-13 南京工业大学 一种碳氮材料负载的钴催化剂及合成哌马色林中间体的方法
US10369190B2 (en) 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
US11464768B2 (en) * 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
MX2019014113A (es) 2017-05-25 2022-08-18 Glytech Llc Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.
KR102609676B1 (ko) 2017-06-12 2023-12-05 글리테크 엘엘씨. Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료
CN109111385B (zh) * 2017-06-23 2023-06-30 上海翰森生物医药科技有限公司 5-ht2a受体抑制剂及其制备方法和应用
WO2019040104A2 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
CN117466803A (zh) 2017-08-21 2024-01-30 阿卡蒂亚药品公司 化合物、其盐和用于治疗疾病的方法
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN109568278A (zh) * 2017-09-28 2019-04-05 北京万全德众医药生物技术有限公司 匹莫范色林片剂及其制备方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11357766B2 (en) * 2017-11-13 2022-06-14 Texas Tech University System Compositions and methods for treating cancer
KR102036909B1 (ko) * 2017-11-28 2019-10-25 한국과학기술원 신규 디스토니아 치료용 약학적 조성물
IT201800003736A1 (it) 2018-03-19 2019-09-19 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Pimavanserin
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
CN108947891B (zh) 2018-07-26 2021-02-09 丽珠集团新北江制药股份有限公司 利用三光气安全制备匹莫范色林及其酒石酸盐的方法
JP7457000B2 (ja) 2018-08-31 2024-03-27 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
KR20210052471A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
IT201800009690A1 (it) 2018-10-23 2020-04-23 Lundbeck Pharmaceuticals Italy Spa Processo per la produzione di pimavanserina
WO2020176599A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
KR20210134928A (ko) 2019-02-27 2021-11-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 n-치환된 인돌 및 다른 헤테로사이클
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20220288048A1 (en) 2019-07-22 2022-09-15 Acadia Pharmaceuticals Inc. Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
KR102227268B1 (ko) * 2019-10-07 2021-03-12 한국과학기술원 디스토니아 치료 후보 약물의 신규 스크리닝 방법
WO2021147818A1 (zh) * 2020-01-21 2021-07-29 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其制备和应用
CN115677723A (zh) * 2020-01-21 2023-02-03 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
WO2021206741A1 (en) * 2020-04-09 2021-10-14 Delahoussaye Kevin Modulating neurotransmitter concentration
WO2022017440A1 (zh) * 2020-07-22 2022-01-27 山东绿叶制药有限公司 5-ht 2a受体抑制剂或反向激动剂及其制备方法和应用
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
EP4241774A1 (en) * 2020-11-04 2023-09-13 Gliacelltech Inc. Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine
CN113292484B (zh) * 2021-06-04 2022-11-15 沈阳药科大学 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA684843A (en) 1964-04-21 P. Roberts Cecil Cap aligning mechanism
US165225A (en) * 1875-07-06 Improvement in hubs
BE794333A (fr) 1972-01-20 1973-07-19 Wyeth John & Brother Ltd Composes heterocycliques azotes therapeutiques
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
JPS5152176A (da) 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
JPS528517A (en) 1975-07-09 1977-01-22 Toyo Autom Kk Fluid line automatic closing system at an earthquake
GB1586468A (en) 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
CA1140119A (en) 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
GB8527052D0 (en) 1985-11-02 1985-12-04 Beecham Group Plc Compounds
GB8621892D0 (en) 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1252227B (it) 1991-12-17 1995-06-05 Ciba Geigy Spa Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
JPH05208517A (ja) 1992-01-31 1993-08-20 Nec Corp 印字制御回路
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1994027967A1 (en) 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
ES2227612T3 (es) 1995-09-29 2005-04-01 Eli Lilly And Company Compuestos espiro como inhibidores de agregacion plaquetaria dependiente del fibrinogeno.
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0960104B1 (en) 1996-04-17 2004-06-16 Bristol-Myers Squibb Pharma Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US5869488A (en) 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
CZ82399A3 (cs) 1996-09-10 1999-06-16 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
DE19643331A1 (de) 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6369077B1 (en) 1997-05-08 2002-04-09 Smithkline Beecham Corporation Protease inhibitors
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
AU764766B2 (en) 1998-04-14 2003-08-28 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
KR100676109B1 (ko) 1998-10-16 2007-02-01 다이이치 아스비오파마 가부시키가이샤 신경보호제로서의 아미노페녹시아세트산 유도체
US6150393A (en) 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6725038B1 (en) 1999-01-26 2004-04-20 Nokia Corporation Method and apparatus for speeding up AAL2 connection setup during handover in advanced cellular networks
AU3771700A (en) 1999-03-24 2000-10-09 Regents Of The University Of California, The Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
KR20020014797A (ko) 1999-05-17 2002-02-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 글루카곤 길항제/역 아고니스트
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6834122B2 (en) 2000-01-22 2004-12-21 Kairos Scientific, Inc. Visualization and processing of multidimensional data using prefiltering and sorting criteria
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
DE60141752D1 (de) * 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
AU2001291830A1 (en) 2000-09-25 2002-04-02 Actelion Pharmaceuticals Ltd. Substituted amino-aza-cycloalkanes useful against malaria
US20020156068A1 (en) 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
CN100372848C (zh) 2001-12-28 2008-03-05 阿卡蒂亚药品公司 作为单胺受体调节剂的螺氮杂环化合物
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
BR0312217A (pt) 2002-06-24 2005-05-10 Acadia Pharm Inc Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
WO2004039322A2 (en) 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
RU2332401C2 (ru) * 2003-01-16 2008-08-27 Акадиа Фармасьютикалз Инк. Селективные обратные агонисты серотонин 2а/2с рецептора, применяемые в качестве лекарственных средств при нейродегенеративных заболеваниях
AU2004206931A1 (en) 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US8304431B2 (en) 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
ATE426405T1 (de) 2003-12-22 2009-04-15 Acadia Pharm Inc Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7868176B2 (en) 2004-09-27 2011-01-11 Acadia Pharmaceuticals, Inc. Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
JP4933450B2 (ja) 2005-01-10 2012-05-16 タヘリ ラドュカ エルエルシー インプラント可能装置を体内で展開するための機器および方法
AU2006229904A1 (en) 2005-03-30 2006-10-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8572080B2 (en) 2010-06-04 2013-10-29 Salesforce.Com, Inc. Methods and systems for analyzing a network feed in a multi-tenant database system environment
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
US20040213816A1 (en) 2004-10-28
WO2004064738A2 (en) 2004-08-05
CN102028949A (zh) 2011-04-27
KR20050094857A (ko) 2005-09-28
US20160250200A1 (en) 2016-09-01
KR101095939B1 (ko) 2011-12-19
US20220241265A1 (en) 2022-08-04
SI1587789T1 (sl) 2009-02-28
JP5184777B2 (ja) 2013-04-17
BRPI0406591B1 (pt) 2018-12-18
BRPI0406591A (pt) 2005-12-20
US9566271B2 (en) 2017-02-14
US8227487B2 (en) 2012-07-24
SG170617A1 (en) 2011-05-30
US20100227885A1 (en) 2010-09-09
ATE512136T1 (de) 2011-06-15
US7994193B2 (en) 2011-08-09
US9211289B2 (en) 2015-12-15
JP2006516284A (ja) 2006-06-29
US20060264465A1 (en) 2006-11-23
CY1108642T1 (el) 2014-04-09
RU2332401C2 (ru) 2008-08-27
US8008323B2 (en) 2011-08-30
RU2005125918A (ru) 2006-02-10
US7713995B2 (en) 2010-05-11
US10525046B2 (en) 2020-01-07
US8377959B2 (en) 2013-02-19
US20150202194A1 (en) 2015-07-23
RU2465267C2 (ru) 2012-10-27
DE602004016288D1 (de) 2008-10-16
HK1083759A1 (en) 2006-07-14
WO2004064738A3 (en) 2004-11-25
ZA200505680B (en) 2006-04-26
AU2004206886A1 (en) 2004-08-05
US8618130B2 (en) 2013-12-31
US20200323836A1 (en) 2020-10-15
US10028944B2 (en) 2018-07-24
US20100227886A1 (en) 2010-09-09
ES2367135T3 (es) 2011-10-28
CN101780080B (zh) 2014-06-04
EP1587789B1 (en) 2008-09-03
MXPA05007568A (es) 2005-09-21
BRPI0406591B8 (pt) 2021-05-25
CN1816524A (zh) 2006-08-09
US20060264466A1 (en) 2006-11-23
EP1587789A2 (en) 2005-10-26
US7601740B2 (en) 2009-10-13
EP2009000A1 (en) 2008-12-31
CN101780080A (zh) 2010-07-21
HK1126776A1 (en) 2009-09-11
US20130137727A1 (en) 2013-05-30
ES2314362T3 (es) 2009-03-16
US20170209424A1 (en) 2017-07-27
US20140140982A1 (en) 2014-05-22
US20120277221A1 (en) 2012-11-01
US20110257229A1 (en) 2011-10-20
JP2010174026A (ja) 2010-08-12
PT1587789E (pt) 2008-12-16
ATE407117T1 (de) 2008-09-15
CA2512639C (en) 2012-10-30
US7659285B2 (en) 2010-02-09
US8921393B2 (en) 2014-12-30
US20240091212A1 (en) 2024-03-21
CN1816524B (zh) 2012-06-27
US20190030015A1 (en) 2019-01-31
AU2004206886B2 (en) 2010-09-02
CA2512639A1 (en) 2004-08-05
EP2009000B1 (en) 2011-06-08
US7732462B2 (en) 2010-06-08
NZ541146A (en) 2009-04-30
DK1587789T3 (da) 2009-01-05
RU2008115009A (ru) 2009-10-27
US20060199842A1 (en) 2006-09-07
SI2009000T1 (sl) 2011-09-30

Similar Documents

Publication Publication Date Title
DK2009000T3 (da) Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
BRPI0418052A2 (pt) derivados de ciclohexano espiro-cíclicos com afinidade para o receptor orl1
DE60302476D1 (de) Versorgungssystem eines Reduktionsmittels
ZA200604791B (en) Hydronopol derivatives as agonists on human ORL1 receptors
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
ATE384697T1 (de) 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
MA28495B1 (fr) Derives d'oxadiazolone agonistes de ppar-delta
BRPI0921097A2 (pt) composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento.
DE60319626D1 (de) Feuchtmittelversorgungsapparat vom Spraytyp
NL1029686A1 (nl) Oxazolidinonen die oxindolen bevatten als antibacteriele middelen.
ITVR20050060A1 (it) Macchina per la pulitura di scale mobili e simili, particolarmente per eseguire la pulizia dell'alzata degli scalini.
ITMI20052077A1 (it) Agente batteriostatica e-o battericida per preparazioni cosmetiche e-o dermofarmaceutiche e preparazioni contenenti questo agente
SE0302794D0 (sv) Novel microparticles for ultrasound contrast imaging and drug delivery
IL175347A0 (en) Hydronopol derivatives as agonists on human orl1 receptors
FR2889055B1 (fr) Appareil d'hydrotherapie contrastee (chaud -froid)
EP1958949A4 (en) THERAPEUTIC AGENT AGAINST HORNHAUT / BINDEHAUT DISEASE
DE50300597D1 (de) Fanghakeneinrichtung für eine Fronthaube eines Kraftfahrzeugs
UA13322S (uk) Пальто жіноче хутрове комбіноване «вишневий йогурт». модель мв
UA11825S (uk) Куртка жіноча хутрова «моніка». модель 20-мв.
ITMI20040411A1 (it) Macchina perfezionata per l'inscatolamento di pesce carne e simili
RU2003120857A (ru) Адаптогенное средство
SE0500053D0 (sv) Therapeutic agents 1
ITLI990008V0 (it) Utilizzo di pupazzi animati, robot/animatronics, animali meccanici, ri produzioni di parti del corpo umano in movimento nel campo pubblicitar
GB0524046D0 (en) Improvement in oral hygiene agents